A retrospective, observational study of utilization of TAK-660 and its clinical profiles before and after switching to TAK-660 in patients with hemophilia A using US Specialty Pharmacy Data
Latest Information Update: 04 Dec 2019
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
Most Recent Events
- 04 Dec 2019 New trial record
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.